9430075 Canada Ltd. entered into a letter of intent to acquire MedGen, Inc. (OTCPK:MDIN) in a reverse merger transaction on October 9, 2019. As a result of the potential acquisition, Bradford Brock resigned as an Officer and Director and Michael Kahiri was appointed as President, Chief Executive Officer and Director of the Magnifind.ca. The transaction is expected to close within the next 60 days. Magnifind.ca entered into a share exchange agreement to acquire MedGen, Inc. in a reverse merger transaction on June 25, 2020. As reported, Magnifind was acquired in a share exchange transaction whereby MedGen issued 1 million shares of its newly created Series C Preferred Stock in exchange for all of the capital stock of Magnifind held by the shareholders of Magnifind. MedGen have the right to vote 70% of the fully diluted shares outstanding of MedGen and, upon an effective registration statement filed with the Securities and Exchange Commission, shall be automatically converted into common stock of MedGen representing 70% of the total shares outstanding on a fully diluted basis. Magnifind will now operate as a wholly owned operating subsidiary of MedGen, The transaction is subject to satisfactory completion of due diligence, no material adverse change, Magnifind shall have provided with reasonable assurances that Magnifind shall have financial statements available to be incorporated into a registration statement and other conditions.

9430075 Canada Ltd. completed the acquisition of MedGen, Inc. (OTCPK:MDIN) in a reverse merger transaction on June 25, 2020.